What Laboratorio Elea Pharma Phoenix does

Laboratorio Elea Pharma Phoenix S.A. is an Argentine pharmaceutical manufacturer, privately held and operating as part of the Insud Group conglomerate, with its headquarters and a 90,000+ m2 GMP-certified industrial plant located in Los Polvorines, Buenos Aires. The company produces a broad portfolio spanning prescription pharmaceuticals across multiple therapeutic areas (oncology, neurology, infectious disease, cardiovascular, metabolic), pharmaceutical-grade cannabidiol (Kanbis, >99% purity), the FDA-approved Chagas disease treatment Abarax (benznidazol), and a large portfolio of over-the-counter consumer health brands including Geniol, Benadryl, Agarol, Adermicina, Caladryl, Evatest, and Mylanta. The company employs 1,300+ people organized across manufacturing, R&D, commercial, and support functions, with a notable 80+ person R&D team.

The company's core technology is built around domestic biotechnology capabilities for monoclonal antibody biosimilar production, anchored by Pembrox — the world's first pembrolizumab biosimilar (launched early 2025), which competes with Merck's Keytruda and triggered an estimated 50% price reduction in Argentina alongside a 1,300% increase in government purchases. It operates dedicated subsidiaries (notably EleaExeltis for oncology biosimilars) and has been recognized as the sole worldwide supplier of FDA-approved Chagas disease medication through WHO/PAHO channels. Strategic academic alliances with Universidad de Buenos Aires, Universidad Maimonides, and Universidad San Pablo de Tucumán support R&D, clinical training, and prescriber engagement.

The business model is multi-channel: government procurement (Argentine Ministry of Health and international organizations like PAHO/WHO), retail pharmacy distribution for OTC and prescription products, and a Global Businesses division handling Latin American exports. Pricing is not publicly disclosed but operates on quote-based government contracts and unit pricing for OTC. The company has been actively expanding — launching multiple specialty products in 2025 (Dutide/semaglutide for metabolic, Tinair for smoking cessation, Tasolol for pain), entering Paraguay organically with Dermolín, and completing the May 2026 acquisition of Cellera Farma for inorganic growth into adjacent Latin American markets.

Name

Laboratorio Elea Pharma Phoenix

Legal name

Laboratorio Elea Phoenix S.A.

Website

https://elea.com

Company type

Private

Founded year

1943

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Laboratorio Elea Pharma Phoenix is an Argentine pharmaceutical manufacturer producing prescription drugs, oncology biosimilars (including the world's first pembrolizumab biosimilar), pharmaceutical-grade CBD, and OTC consumer health brands, serving government health programs, pharmacies, and international health organizations across Latin America.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

Keywords

• Pharmaceutical manufacturing
• Prescription medications
• Biosimilar development
• Over-the-counter products
• Oncology therapeutics

Headquarters

HQ city

Los Polvorines

HQ country

Argentina

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Prescription Pharmaceuticals: Revenue from prescription medications across multiple therapeutic areas including oncology, neurology, infectious diseases, cardiovascular, and metabolic disorders
2. Over-the-Counter (OTC) Products: Revenue from OTC consumer health products sold through pharmacies and retail channels including supplements, analgesics, and personal care
3. Government Health Program Supply: Supply of pharmaceuticals to Argentine government health programs including treatments for cancer, Chagas disease, and other conditions through public procurement
4. International Export: Global businesses division exports pharmaceutical products to Latin America and other international markets

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Laboratorio Elea Phoenix is an Argentine pharmaceutical laboratory that develops, manufactures, and commercializes a broad portfolio of prescription and over-the-counter (OTC) medications. Its portfolio spans oncology biosimilars (including Pembrox, the world's first pembrolizumab biosimilar), neurology products (Kanbis pharmaceutical-grade CBD for epilepsy), neglected disease treatments (Abarax for Chagas disease), primary care, and consumer health brands. The company operates a GMP-certified 90,000+ m2 manufacturing plant in Argentina and supplies both domestic government health programs and international markets.

Differentiator

Problem solved

Functional benefit

Brands

• EleaExeltis: Oncology and specialty treatments division of Elea, including biosimilars and cancer treatments.
• Kanbis
• Pembrox

Products and services

• Pembrox (pembrolizumab biosimilar) Monoclonal antibody biosimilar used for cancer immunotherapy, the first global biosimilar of Merck's Keytruda, sold to government health programs and the public healthcare system in Argentina.
• Kanbis / Kanbis CBD Highly purified pharmaceutical-grade cannabidiol (>99% purity) indicated for epilepsy including treatment-resistant forms (Lennox-Gastaut, Dravet), chronic pain, anxiety, and sleep disorders, supplied to healthcare professionals and patients.
• Abarax (benznidazol) Benznidazole-based treatment for Chagas disease; only FDA-approved treatment supplied worldwide by Elea and distributed through PAHO/WHO essential medicines programs.
• Dutide (Semaglutida en comprimidos) Oral semaglutide tablet indicated for metabolic disorders and obesity treatment, sold through pharmacy distribution.
• Tinair (Citisiniclina) Cytisinicline-based treatment for smoking cessation, addressing physical, psychological, and behavioral dependence on nicotine.
• Tasolol (Tapentadol) Tapentadol indicated for treatment of chronic pain with a more favorable gastrointestinal side-effect profile than other opioids.
• OTC Consumer Health Brands (Adermicina, Agarol Pur, Alernix, Aziatop, Benadryl, Caladryl, Cedric, Contractil, Evacare, Evatest, Geniol, Mylanta, Pervinox, etc.) Wide portfolio of over-the-counter consumer health products including analgesics, dermatological products, gastrointestinal treatments, allergy medications, vitamins, and personal care items sold directly to consumers through retail pharmacies.
• Dermolín Agua Micelar (Adermicina line extension) 5-in-1 micellar water (removes makeup, cleanses, tones, moisturizes, and decongests) launched in Paraguay as an extension of the Adermicina dermatological consumer health line.

Quantifiable outcome

• 50% price reduction for Keytruda in Argentina after Pembrox entry
• +2 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered parent, core and minor.

• Insud GroupparentStrategic or Co-development PartnerLaboratorio Elea is part of Insud Group, a larger Argentine pharmaceutical conglomerate enabling shared resources, R&D capabilities, and market reach
• Universidad de Buenos Aires (UBA) - Faculty of MedicinecoreStrategic or Co-development PartnerStrategic cooperation agreement with the Faculty of Medicine of UBA for research, training, and academic collaboration
• Universidad de Buenos Aires (UBA) - Faculty of LawcoreStrategic or Co-development PartnerAgreement with the Health Observatory of the Faculty of Law for joint projects
• Universidad MaimonidescoreStrategic or Co-development PartnerTraining and education programs for medical residents in cardiology, gynecology, pulmonology, and neurology; collaboration in simulation and quality care
• Universidad San Pablo de TucumanminorStrategic or Co-development PartnerCollaboration on Diplomatura (diploma program) in cannabis and derivatives for medical use
• Argentine Association for the Study of Climacteric (AAPEC)minorStrategic or Co-development PartnerCollaboration on preventive health practices for women's health through the Mujeres Salud Integral initiative
• Pan American Health Organization (PAHO)coreOthersInternational procurement partner for Chagas disease medication Abarax through PAHO/WHO programs
• World Health Organization (WHO)coreOthersGlobal supply partner for Chagas disease treatment through WHO essential medicines programs
• Argentine Ministry of HealthcoreOthersGovernment procurement of oncology medications and healthcare products for public health system

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Laboratorios Bagó: Argentine pharmaceutical group of comparable scale and product breadth across branded Rx, OTC, and hospital specialty. Closest direct comp for Elea within Argentina given overlapping therapeutic coverage, hospital presence, and export footprint.
• Roemmers: Major Argentine pharmaceutical laboratory with a comparable branded Rx, OTC, and specialty portfolio and similar regional export footprint. Direct domestic peer across multiple therapeutic categories Elea competes in.
• Laboratorios Richmond: Argentine pharmaceutical company with branded generics and specialty products, including notable biosimilar and HIV franchise activity. Direct peer in domestic branded and public-sector supply channels.
• Gador: Argentine pharmaceutical manufacturer with a similar branded prescription and specialty focus, including oncology and hospital lines. Direct peer given overlapping physician-channel coverage and mid-large Argentine manufacturing scale.
• mAbxience: Argentine biosimilar manufacturer (also within the Insud Group ecosystem) specializing in monoclonal antibody biosimilars such as rituximab, trastuzumab, and bevacizumab. Closest functional peer to Elea's Pembrox biosimilar capability.

Emerging players

• Biocon Biologics: India-headquartered global biosimilar leader with commercialized monoclonal antibody biosimilars (trastuzumab, bevacizumab, adalimumab, etc.). Comparable to Elea's Pembrox ambitions in oncology biosimilars and emerging-market commercialization model.

Broad incumbents

• Dr. Reddy's Laboratories: Large Indian pharmaceutical company with a meaningful biosimilars, generics, and branded specialty portfolio across emerging markets. Comparable to Elea on the breadth of branded + biosimilar + OTC exposure across price-sensitive geographies.
• Teva Pharmaceutical Industries: Global generics and biosimilars incumbent with extensive emerging-market presence and a mature biosimilar pipeline. Broad incumbent peer relevant to evaluating how a scaled global biosimilar franchise is monetized across tender and retail channels.

Regional players

• Eurofarma Laboratórios: Brazil's largest privately held pharmaceutical company with a broad branded, generic, and biotech portfolio across Latin America. Regional peer given shared geographic focus and similarly diversified business units.
• Genomma Lab Internacional: Mexican-headquartered Latin American OTC and personal-care pharmaceutical company with strong brand-building and channel reach. Comparable to Elea on the OTC/consumer health division and Latin American brand-portfolio model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC3ayeLH3pu6lJqPywz3odsA
• Facebookfacebook.com/laboratorioelea
• LinkedInlinkedin.com/company/laboratorio-eleaphoenix

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laboratorio Elea Pharma Phoenix